Please assess the completion status of the following clinical trial:

Trial Title: Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All pediatric febrile neutropenia patients treated on outpatient basis~* Age 3 years - 18 years~* Fulfilling low risk criteria ( Hematological malignancies in remission, No identifiable focus of infection, No Pneumonia/ mucositis / GI sepsis / Nausea-vomiting/ neurologic-mental status changes/ Central Venous Catheter (CVC) related infection, Anticipated Absolute Neutrophil Count (ANC) recovery ≤ 10 days, No organ dysfunction, Hemodynamically stable, Culture negative )~* Afebrile for at least 24 hours, on intra-venous antibiotics~Exclusion Criteria:~* Bone marrow involvement in solid tumor~* Already enrolled once, in previous episode~* On antibiotics prophylaxis~* Retroviral positive patients~* Patient undergone stem cell transplant

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- arm (A) - stoppage of antibiotics (Type: EXPERIMENTAL): patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. Antibiotics will be stopped in Arm-A.
- arm (B) - oral antibiotics till ANC ≥ 500 (Type: ACTIVE_COMPARATOR): patients will be reassessed for randomization once they fulfill all inclusion criteria and get afebrile for at least 24 hours. oral antibiotics, in place of intravenous antibiotics, will be started in Arm-B.

Based on this trial design, predict the completion outcome and termination type (if applicable).